|
gptkbp:instanceOf
|
gptkb:small_molecule
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:alternativeName
|
gptkb:tofacitinib
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L04AA29
|
|
gptkbp:CASNumber
|
540737-29-9
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
3 hours
|
|
gptkbp:hasMolecularFormula
|
C16H20N6O
|
|
gptkbp:hasSMILES
|
CC1=CC(=NC=N1)N2CCN(CC2)C3=NC=NC(=O)N3C
|
|
gptkbp:hasUNII
|
FFL0D5469V
|
|
gptkbp:KEGGID
|
D09960
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:Janus_kinase_inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP2C19
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
312.37 g/mol
|
|
gptkbp:PubChem_CID
|
9926791
DB08895
8106452
CHEMBL385118
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
headache
hypertension
infections
increased cholesterol
|
|
gptkbp:target
|
gptkb:JAK1
gptkb:JAK3
|
|
gptkbp:usedFor
|
gptkb:psoriatic_arthritis
ulcerative colitis
rheumatoid arthritis
|
|
gptkbp:bfsParent
|
gptkb:tofacitinib
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CP-690,550
|